E
0913693 B.C. Ltd.
RP.V
TSX
E
Sell
3/19/2025Downgrade
0913693 B.C. Ltd. (RP.V) was downgraded to E+ from D on 3/19/2025 due to a significant decline in the valuation index and efficiency index.
0913693 B.C. Ltd. (RP.V) was downgraded to E+ from D on 3/19/2025 due to a significant decline in the valuation index and efficiency index.
D
Sell
2/14/2025Upgraded
RepliCel Life Sciences Inc. (RP.V) was upgraded to D from D- on 2/14/2025 due to an increase in the volatility index and growth index.
RepliCel Life Sciences Inc. (RP.V) was upgraded to D from D- on 2/14/2025 due to an increase in the volatility index and growth index.
D
Sell
1/30/2025Downgrade
RepliCel Life Sciences Inc. (RP.V) was downgraded to D- from D on 1/30/2025 due to a decline in the efficiency index, total return index and volatility index. Net income declined 15.44% from -$137.3 to -$158.5, and total capital declined 5.39% from -$2.73M to -$2.88M.
RepliCel Life Sciences Inc. (RP.V) was downgraded to D- from D on 1/30/2025 due to a decline in the efficiency index, total return index and volatility index. Net income declined 15.44% from -$137.3 to -$158.5, and total capital declined 5.39% from -$2.73M to -$2.88M.
D
Sell
6/14/2024Upgraded
RepliCel Life Sciences Inc. (RP.V) was upgraded to D from E+ on 6/14/2024 due to a major increase in the efficiency index and total return index.
RepliCel Life Sciences Inc. (RP.V) was upgraded to D from E+ on 6/14/2024 due to a major increase in the efficiency index and total return index.
E
Sell
4/26/2024Downgrade
RepliCel Life Sciences Inc. (RP.V) was downgraded to E+ from D- on 4/26/2024 due to a decline in the volatility index.
RepliCel Life Sciences Inc. (RP.V) was downgraded to E+ from D- on 4/26/2024 due to a decline in the volatility index.
D
Sell
4/11/2024Upgraded
RepliCel Life Sciences Inc. (RP.V) was upgraded to D- from E+ on 4/11/2024 due to a significant increase in the valuation index and volatility index.
RepliCel Life Sciences Inc. (RP.V) was upgraded to D- from E+ on 4/11/2024 due to a significant increase in the valuation index and volatility index.
E
Sell
10/26/2023Downgrade
RepliCel Life Sciences Inc. (RP.V) was downgraded to E+ from D- on 10/26/2023 due to a decline in the volatility index, total return index and valuation index.
RepliCel Life Sciences Inc. (RP.V) was downgraded to E+ from D- on 10/26/2023 due to a decline in the volatility index, total return index and valuation index.
D
Sell
10/11/2023Upgraded
RepliCel Life Sciences Inc. (RP.V) was upgraded to D- from E+ on 10/11/2023 due to an increase in the volatility index.
RepliCel Life Sciences Inc. (RP.V) was upgraded to D- from E+ on 10/11/2023 due to an increase in the volatility index.
E
Sell
9/26/2023Downgrade
RepliCel Life Sciences Inc. (RP.V) was downgraded to E+ from D- on 9/26/2023 due to a major decline in the growth index, volatility index and valuation index. Operating cash flow declined 367.57% from -$177.3 to -$829, earnings per share declined from $0.0372 to -$0.0137, and EBIT declined 21.02% from -$282.6 to -$342.
RepliCel Life Sciences Inc. (RP.V) was downgraded to E+ from D- on 9/26/2023 due to a major decline in the growth index, volatility index and valuation index. Operating cash flow declined 367.57% from -$177.3 to -$829, earnings per share declined from $0.0372 to -$0.0137, and EBIT declined 21.02% from -$282.6 to -$342.
D
Sell
3/14/2023Downgrade
RepliCel Life Sciences Inc. (RP.V) was downgraded to D- from D on 3/14/2023 due to a decline in the valuation index.
RepliCel Life Sciences Inc. (RP.V) was downgraded to D- from D on 3/14/2023 due to a decline in the valuation index.
D
Sell
2/9/2023Upgraded
RepliCel Life Sciences Inc. (RP.V) was upgraded to D from E+ on 2/9/2023 due to an increase in the volatility index and total return index.
RepliCel Life Sciences Inc. (RP.V) was upgraded to D from E+ on 2/9/2023 due to an increase in the volatility index and total return index.
E
Sell
2/8/2023Downgrade
RepliCel Life Sciences Inc. (RP.V) was downgraded to E+ from D on 2/8/2023 due to a decline in the volatility index, total return index and solvency index. The quick ratio declined from 0.18 to 0.09.
RepliCel Life Sciences Inc. (RP.V) was downgraded to E+ from D on 2/8/2023 due to a decline in the volatility index, total return index and solvency index. The quick ratio declined from 0.18 to 0.09.
D
Sell
7/7/2022Upgraded
RepliCel Life Sciences Inc. (RP.V) was upgraded to D from D- on 7/7/2022 due to an increase in the growth index, volatility index and total return index. Operating cash flow increased 36.1% from -$415.5 to -$265.5, EBIT increased 25.52% from -$373 to -$277.8, and earnings per share increased from -$0.0224 to -$0.0178.
RepliCel Life Sciences Inc. (RP.V) was upgraded to D from D- on 7/7/2022 due to an increase in the growth index, volatility index and total return index. Operating cash flow increased 36.1% from -$415.5 to -$265.5, EBIT increased 25.52% from -$373 to -$277.8, and earnings per share increased from -$0.0224 to -$0.0178.
D
Sell
7/1/2022Downgrade
RepliCel Life Sciences Inc. (RP.V) was downgraded to D- from D on 7/1/2022 due to a decline in the growth index, total return index and volatility index. Operating cash flow declined 44.37% from -$287.8 to -$415.5, and earnings per share declined from -$0.0207 to -$0.0224.
RepliCel Life Sciences Inc. (RP.V) was downgraded to D- from D on 7/1/2022 due to a decline in the growth index, total return index and volatility index. Operating cash flow declined 44.37% from -$287.8 to -$415.5, and earnings per share declined from -$0.0207 to -$0.0224.
D
Sell
5/16/2022Upgraded
RepliCel Life Sciences Inc. (RP.V) was upgraded to D from E+ on 5/16/2022 due to an increase in the volatility index.
RepliCel Life Sciences Inc. (RP.V) was upgraded to D from E+ on 5/16/2022 due to an increase in the volatility index.
E
Sell
5/13/2022Downgrade
RepliCel Life Sciences Inc. (RP.V) was downgraded to E+ from D on 5/13/2022 due to a decline in the total return index.
RepliCel Life Sciences Inc. (RP.V) was downgraded to E+ from D on 5/13/2022 due to a decline in the total return index.
D
Sell
5/5/2022Upgraded
RepliCel Life Sciences Inc. (RP.V) was upgraded to D from D- on 5/5/2022 due to an increase in the valuation index.
RepliCel Life Sciences Inc. (RP.V) was upgraded to D from D- on 5/5/2022 due to an increase in the valuation index.
D
Sell
4/20/2022Downgrade
RepliCel Life Sciences Inc. (RP.V) was downgraded to D- from D on 4/20/2022 due to a substantial decline in the total return index and growth index. Total revenue declined 2.5% from $72 to $70.2.
RepliCel Life Sciences Inc. (RP.V) was downgraded to D- from D on 4/20/2022 due to a substantial decline in the total return index and growth index. Total revenue declined 2.5% from $72 to $70.2.
D
Sell
11/23/2021Upgraded
0913693 B.C. Ltd. (RP.V) was upgraded to D from D- on 11/23/2021.
0913693 B.C. Ltd. (RP.V) was upgraded to D from D- on 11/23/2021.
D
Sell
11/8/2021Downgrade
0913693 B.C. Ltd. (RP.V) was downgraded to D- from D on 11/08/2021.
0913693 B.C. Ltd. (RP.V) was downgraded to D- from D on 11/08/2021.
D
Sell
12/30/2020Upgraded
RepliCel Life Sciences Inc. (RP.V) was upgraded to D from D- on 12/30/2020 due to an increase in the total return index.
RepliCel Life Sciences Inc. (RP.V) was upgraded to D from D- on 12/30/2020 due to an increase in the total return index.
D
Sell
12/2/2020Downgrade
RepliCel Life Sciences Inc. (RP.V) was downgraded to D- from D on 12/2/2020 due to a substantial decline in the solvency index, total return index and growth index. Operating cash flow declined 1,006.27% from -$59 to -$652.7, EBIT declined 96.63% from -$198.9 to -$391.1, and earnings per share declined from -$0.0084 to -$0.015.
RepliCel Life Sciences Inc. (RP.V) was downgraded to D- from D on 12/2/2020 due to a substantial decline in the solvency index, total return index and growth index. Operating cash flow declined 1,006.27% from -$59 to -$652.7, EBIT declined 96.63% from -$198.9 to -$391.1, and earnings per share declined from -$0.0084 to -$0.015.
D
Sell
5/1/2020Downgrade
RepliCel Life Sciences Inc. (RP.V) was downgraded to D from D+ on 5/1/2020 due to a significant decline in the efficiency index and solvency index.
RepliCel Life Sciences Inc. (RP.V) was downgraded to D from D+ on 5/1/2020 due to a significant decline in the efficiency index and solvency index.
D
Sell
11/29/2019Upgraded
RepliCel Life Sciences Inc. (RP.V) was upgraded to D+ from D on 11/29/2019 due to a significant increase in the efficiency index, solvency index and growth index. Operating cash flow increased 59.36% from -$667.4 to -$271.2, EBIT increased 39.05% from -$697.8 to -$425.3, and earnings per share increased from -$0.0259 to -$0.0158.
RepliCel Life Sciences Inc. (RP.V) was upgraded to D+ from D on 11/29/2019 due to a significant increase in the efficiency index, solvency index and growth index. Operating cash flow increased 59.36% from -$667.4 to -$271.2, EBIT increased 39.05% from -$697.8 to -$425.3, and earnings per share increased from -$0.0259 to -$0.0158.
D
Sell
5/2/2019Downgrade
RepliCel Life Sciences Inc. (RP.V) was downgraded to D from D+ on 5/2/2019 due to a significant decline in the efficiency index and volatility index. Net income declined 18.08% from -$585.3 to -$691.1.
RepliCel Life Sciences Inc. (RP.V) was downgraded to D from D+ on 5/2/2019 due to a significant decline in the efficiency index and volatility index. Net income declined 18.08% from -$585.3 to -$691.1.
D
Sell
11/26/2018Upgraded
RepliCel Life Sciences Inc. (RP.V) was upgraded to D+ from D on 11/26/2018 due to a significant increase in the efficiency index, total return index and volatility index.
RepliCel Life Sciences Inc. (RP.V) was upgraded to D+ from D on 11/26/2018 due to a significant increase in the efficiency index, total return index and volatility index.
D
Sell
5/11/2018Upgraded
RepliCel Life Sciences Inc. (RP.V) was upgraded to D from D- on 5/11/2018 due to an increase in the growth index. Earnings per share increased from -$0.0509 to -$0.0235, and EBIT increased 52.49% from -$969.2 to -$460.5.
RepliCel Life Sciences Inc. (RP.V) was upgraded to D from D- on 5/11/2018 due to an increase in the growth index. Earnings per share increased from -$0.0509 to -$0.0235, and EBIT increased 52.49% from -$969.2 to -$460.5.
D
Sell
4/24/2018Downgrade
RepliCel Life Sciences Inc. (RP.V) was downgraded to D- from D on 4/24/2018 due to a decline in the volatility index.
RepliCel Life Sciences Inc. (RP.V) was downgraded to D- from D on 4/24/2018 due to a decline in the volatility index.
D
Sell
12/26/2017Upgraded
RepliCel Life Sciences Inc. (RP.V) was upgraded to D from D- on 12/26/2017 due to an increase in the volatility index.
RepliCel Life Sciences Inc. (RP.V) was upgraded to D from D- on 12/26/2017 due to an increase in the volatility index.
D
Sell
12/1/2017Upgraded
RepliCel Life Sciences Inc. (RP.V) was upgraded to D- from E+ on 12/1/2017 due to a large increase in the growth index, valuation index and efficiency index. Operating cash flow increased 74.89% from -$1.66M to -$416.6, earnings per share increased from -$0.0996 to -$0.0509, and net income increased 48.86% from -$1.86M to -$948.8.
RepliCel Life Sciences Inc. (RP.V) was upgraded to D- from E+ on 12/1/2017 due to a large increase in the growth index, valuation index and efficiency index. Operating cash flow increased 74.89% from -$1.66M to -$416.6, earnings per share increased from -$0.0996 to -$0.0509, and net income increased 48.86% from -$1.86M to -$948.8.
E
Sell
8/31/2017Downgrade
RepliCel Life Sciences Inc. (RP.V) was downgraded to E+ from D- on 8/31/2017 due to a noticeable decline in the growth index, solvency index and volatility index. The quick ratio declined from 4.42 to 1.17, EBIT declined 44.41% from -$1.28M to -$1.85M, and earnings per share declined from -$0.0773 to -$0.0996.
RepliCel Life Sciences Inc. (RP.V) was downgraded to E+ from D- on 8/31/2017 due to a noticeable decline in the growth index, solvency index and volatility index. The quick ratio declined from 4.42 to 1.17, EBIT declined 44.41% from -$1.28M to -$1.85M, and earnings per share declined from -$0.0773 to -$0.0996.
D
Sell
6/2/2017Upgraded
RepliCel Life Sciences Inc. (RP.V) was upgraded to D- from E+ on 6/2/2017 due to a noticeable increase in the growth index, solvency index and valuation index. The quick ratio increased from 2.54 to 4.42, earnings per share increased from -$0.1096 to -$0.0773, and operating cash flow increased 22.93% from -$1.84M to -$1.42M.
RepliCel Life Sciences Inc. (RP.V) was upgraded to D- from E+ on 6/2/2017 due to a noticeable increase in the growth index, solvency index and valuation index. The quick ratio increased from 2.54 to 4.42, earnings per share increased from -$0.1096 to -$0.0773, and operating cash flow increased 22.93% from -$1.84M to -$1.42M.
E
Sell
5/30/2017Downgrade
RepliCel Life Sciences Inc. (RP.V) was downgraded to E+ from D- on 5/30/2017 due to a decline in the total return index, volatility index and valuation index.
RepliCel Life Sciences Inc. (RP.V) was downgraded to E+ from D- on 5/30/2017 due to a decline in the total return index, volatility index and valuation index.
D
Sell
5/17/2017Downgrade
RepliCel Life Sciences Inc. (RP.V) was downgraded to D- from D+ on 5/17/2017 due to a significant decline in the efficiency index, growth index and valuation index. Operating cash flow declined 2,027.4% from -$86.5 to -$1.84M, EBIT declined 170.96% from -$489 to -$1.33M, and net income declined 165.92% from -$499.4 to -$1.33M.
RepliCel Life Sciences Inc. (RP.V) was downgraded to D- from D+ on 5/17/2017 due to a significant decline in the efficiency index, growth index and valuation index. Operating cash flow declined 2,027.4% from -$86.5 to -$1.84M, EBIT declined 170.96% from -$489 to -$1.33M, and net income declined 165.92% from -$499.4 to -$1.33M.
D
Sell
1/10/2017Upgraded
RepliCel Life Sciences Inc. (RP.V) was upgraded to D+ from D on 1/10/2017 due to an increase in the total return index and volatility index.
RepliCel Life Sciences Inc. (RP.V) was upgraded to D+ from D on 1/10/2017 due to an increase in the total return index and volatility index.
D
Sell
12/1/2016Upgraded
RepliCel Life Sciences Inc. (RP.V) was upgraded to D from D- on 12/1/2016 due to a significant increase in the efficiency index, valuation index and growth index. Operating cash flow increased 80.79% from -$450.8 to -$86.6, EBIT increased 19.82% from -$610.6 to -$489.6, and earnings per share increased from -$0.091 to -$0.0743.
RepliCel Life Sciences Inc. (RP.V) was upgraded to D from D- on 12/1/2016 due to a significant increase in the efficiency index, valuation index and growth index. Operating cash flow increased 80.79% from -$450.8 to -$86.6, EBIT increased 19.82% from -$610.6 to -$489.6, and earnings per share increased from -$0.091 to -$0.0743.
D
Sell
3/11/2016Downgrade
RepliCel Life Sciences Inc. (RP.V) was downgraded to D- from D on 3/11/2016 due to a large decline in the volatility index, total return index and solvency index. The quick ratio declined from 2.27 to 0.72.
RepliCel Life Sciences Inc. (RP.V) was downgraded to D- from D on 3/11/2016 due to a large decline in the volatility index, total return index and solvency index. The quick ratio declined from 2.27 to 0.72.
D
Sell
3/17/2015Upgraded
RepliCel Life Sciences Inc. (RP.V) was upgraded to D from D- on 3/17/2015 due to an increase in the total return index and volatility index.
RepliCel Life Sciences Inc. (RP.V) was upgraded to D from D- on 3/17/2015 due to an increase in the total return index and volatility index.
D
Sell
3/2/2015Downgrade
RepliCel Life Sciences Inc. (RP.V) was downgraded to D- from D on 3/2/2015 due to a decline in the total return index.
RepliCel Life Sciences Inc. (RP.V) was downgraded to D- from D on 3/2/2015 due to a decline in the total return index.
D
Sell
2/2/2015Upgraded
RepliCel Life Sciences Inc. (RP.V) was upgraded to D from D- on 2/2/2015 due to a noticeable increase in the efficiency index and valuation index.
RepliCel Life Sciences Inc. (RP.V) was upgraded to D from D- on 2/2/2015 due to a noticeable increase in the efficiency index and valuation index.
D
Sell
10/1/2014Upgraded
RepliCel Life Sciences Inc. (RP.V) was upgraded to D- from E on 10/1/2014 due to an increase in the valuation index.
RepliCel Life Sciences Inc. (RP.V) was upgraded to D- from E on 10/1/2014 due to an increase in the valuation index.
E
Sell
7/1/2014Upgraded
RepliCel Life Sciences Inc. (RP.V) was upgraded to E from E- on 7/1/2014 due to an increase in the growth index. Earnings per share increased from -$0.0214 to -$0.0231.
RepliCel Life Sciences Inc. (RP.V) was upgraded to E from E- on 7/1/2014 due to an increase in the growth index. Earnings per share increased from -$0.0214 to -$0.0231.
E
Sell
5/27/2014Downgrade
RepliCel Life Sciences Inc. (RP.V) was downgraded to E- from E on 5/27/2014 due to a decline in the volatility index.
RepliCel Life Sciences Inc. (RP.V) was downgraded to E- from E on 5/27/2014 due to a decline in the volatility index.
E
Sell
5/9/2014Upgraded
RepliCel Life Sciences Inc. (RP.V) was upgraded to E from E- on 5/9/2014 due to an increase in the volatility index.
RepliCel Life Sciences Inc. (RP.V) was upgraded to E from E- on 5/9/2014 due to an increase in the volatility index.
E
Sell
4/23/2014Downgrade
RepliCel Life Sciences Inc. (RP.V) was downgraded to E- from E on 4/23/2014 due to a decline in the volatility index.
RepliCel Life Sciences Inc. (RP.V) was downgraded to E- from E on 4/23/2014 due to a decline in the volatility index.
E
Sell
4/8/2014Upgraded
RepliCel Life Sciences Inc. (RP.V) was upgraded to E from on 4/8/2014 due to a significant increase in the solvency index, efficiency index and volatility index.
RepliCel Life Sciences Inc. (RP.V) was upgraded to E from on 4/8/2014 due to a significant increase in the solvency index, efficiency index and volatility index.
